Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer

2.1 Nivolumab (Opdivo, Bristol Myers Squibb) as monotherapy is indicated for 'the adjuvant treatment of adult patients with completely resected oesophageal or gastro‑oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 Nivolumab is available in 3 different sizes as a concentrate for solution for infusion vials. The cost varies according to vial size: £439 (40 mg per 4 ml), £1,097 (100 mg per 10 ml) and £2,633 (240 mg per 24 ml; excluding VAT; BNF online, accessed August 2021). The cost for 1 dose of treatment is £2,633 (240 mg per 24 ml).

2.4 The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.